A phase I pharmacokinetic study of PM00104 (Zalypsis((R))) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. - Capdevila, J; Clive, S; Casado, E; Michie, C; Piera, A; Sicart, E; Carreras, M J; Coronado, C; Kahatt, C; Soto Matos-Pita, A; Fernandez Teruel, C; Siguero, M; et al. (Cancer Chemotherapy & Pharmacology, 2013)